Zoledronic and Hypophosphataemia - a phase IV clinical study of FDA data

Summary:

Hypophosphataemia is reported as a side effect among people who take Zoledronic (zoledronic acid), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Calcium, and have Metastases to bone.

The phase IV clinical study analyzes which people have Hypophosphataemia when taking Zoledronic. It is created by eHealthMe based on reports of 29,760 people who have side effects when taking Zoledronic from the FDA, and is updated regularly.

What is Zoledronic?

Zoledronic has active ingredients of zoledronic acid. eHealthMe is studying from 29,812 Zoledronic users. Check the latest studies of Zoledronic.

What is Hypophosphataemia?

Hypophosphataemia (electrolyte disturbance in which there is an abnormally low level of phosphate in the blood) is found to be associated with 895 drugs and 776 conditions by eHealthMe. Check the latest studies of Hypophosphataemia.

On Feb, 10, 2026

29,760 people reported to have side effects when taking Zoledronic.
Among them, 263 people (0.88%) have Hypophosphataemia.

Could Zoledronic cause Hypophosphataemia?

Among these 263 people:

How long have people been on Zoledronic when they have Hypophosphataemia? *

Click here to view more results

What is the gender of people who have Hypophosphataemia when taking Zoledronic? *

Click here to view

* Approximation only. Some reports may have incomplete information.

Do you take Zoledronic and have Hypophosphataemia?

- Check whether Hypophosphataemia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Zoledronic:

Zoledronic (29,812 reports)

Hypophosphataemia treatments and more:

Hypophosphataemia (10,530 reports)

How severe was Hypophosphataemia and when was it recovered:

Hypophosphataemia in Zoledronic

Expand to all the drugs that have ingredients of zoledronic acid:

Hypophosphataemia and drugs with ingredients of zoledronic acid (602 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Zoledronic:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hypophosphataemia:

Hypophosphataemia (896 drugs)

Browse all the conditions that are associated with Hypophosphataemia:

Hypophosphataemia (776 conditions)

Related publications that referenced our studies

Mariappan R, Prasad A, Venkatraghavan L, "An uncommon cause for severe hypophosphataemia after transsphenoidal pituitary surgery", Journal of Neuroanaesthesiology and Critical Care, 2014 May .
Mariappan R, Prasad A, Venkatraghavan L, "An uncommon cause for severe hypophosphataemia after transsphenoidal pituitary surgery", Journal of Neuroanaesthesiology and Critical Care, 2014 May .

How the study uses the data?

The study uses data from the FDA. It is based on zoledronic acid (the active ingredients of Zoledronic) and Zoledronic (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.